Sleep Quality among Breast and Prostate Cancer Patients: A Comparison between Subjective and Objective Measurements

Breast and prostate cancer patients may experience physical and psychological distress, and a possible decrease in sleep quality. Subjective and objective methods measure different aspects of sleep quality. Our study attempted to determine differences between objective and subjective measurements of sleep quality using bivariate and Pearson’s correlation data analysis. Forty breast (n = 20) and prostate (n = 20) cancer patients were recruited in this observational study. Participants were given an actigraphy device (ACT) and asked to continuously wear it for seven consecutive days, for objective data collection. Following this period, they filled out the Pittsburgh Sleep Quality Index Questionnaire (PSQI) to collect subjective data on sleep quality. The correlation results showed that, for breast cancer patients, PSQI sleep duration was moderately correlated with ACT total sleeping time (TST) (r = −0.534, p < 0.05), and PSQI daytime dysfunction was related to ACT efficiency (r = 0.521, p < 0.05). For prostate cancer patients, PSQI sleep disturbances were related to ACT TST (r = 0.626, p < 0.05). Both objective and subjective measurements are important in validating and determining details of sleep quality, with combined results being more insightful, and can also help in personalized care to further improve quality of life among cancer patients.

Download Full-text

Measurement of DKK1 and FRP in breast and prostate cancer patients with bone metastases: Impact of zoledronic acid (ZA)

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.19659 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 19659-19659

Author(s):

T. Helsten ◽

M. Corr ◽

J. E. Mortimer

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Post Treatment ◽

Bone Homeostasis ◽

Breast Cancer Patients ◽

Bone Specific Alkaline Phosphatase ◽

Osteoblast Activity ◽

Breast And Prostate Cancer

19659 Background: Bone metastases produce an imbalance in osteoblast and osteoclast activity. While metastases from prostate cancer are osteoblastic, metastases from breast cancer may be osteolytic, osteoblastic or mixed. The wnt/frizzled pathway is involved in maturation of osteoblasts and in adult bone homeostasis. We explored the wnt antagonists dickkopf (DKK1) and frizzled related protein (FRP) as potential biomarkers in bone metastasis after ZA treatment. Methods: This is a pilot cohort study in bisphosphonate naive breast and prostate cancer patients with bone metastases. Cancer therapy was not specified. Patients received 2 monthly doses of ZA 4 mg IV. Pre- and post-treatment (day 60) sera were collected for measurement of FRP and DKK1, along with IL-6, calcium, creatinine and bone-specific alkaline phosphatase (BAP, a marker of osteoblast activity). Primary endpoint: mean change in FRP and DKK1; Secondary endpoints: correlation of biomarkers with each other and comparison of breast vs. prostate cancer patients. Biomarkers were measured using standard ELISA assays. Statistics: comparison of means = student t-test, correlation coefficients = Pearson. Results: Mature data from 14 patients are reported here, 9 with breast and 5 with prostate cancer. Mean age = 61 years (range 42–89). Two breast cancer patients were premenopausal. One prostate and 3 breast cancer patients received chemotherapy; all others were treated hormonally. After ZA, calcium decreased in all patients (p = 0.09). BAP decreased in all but 1 breast and 1 prostate cancer patient (mean decrease 20.0, p = 0.16). IL-6 was undetectable in most patients. FRP decreased in all but 4 patients (mean decrease 6.2, p = 0.13). There was no discernable pattern for DKK1. Pre-treatment DKK1 correlated with FRP (p = 0.01, r2 = 0.39), but there was no correlation post-treatment. Post-treatment DKK1 correlated with both serum calcium (p = 0.04, r2 = 0.49) and BAP (p = 0.005, r2 = 0.65). There was no difference between breast and prostate cancer patients. Conclusions: It is feasible to measure DKK1 and FRP in patients with malignant bone disease. Treatment with ZA has measurable effects upon these and other serum markers. Further studies with more patients are needed to evaluate their potential as biomarkers. No significant financial relationships to disclose.

Download Full-text

The prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single-institution experience.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.4_suppl.283 ◽

2014 ◽

Vol 32 (4_suppl) ◽

pp. 283-283

Author(s):

Amarnath Challapalli ◽

Waqar Saleem ◽

Ernese Gjafa ◽

Marc Laniado ◽

Bente Stanbridge ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Hormonal Therapy ◽

Sleep Disturbances ◽

Psychological Symptoms ◽

Therapeutic Modality ◽

Severe Toxicity ◽

Breast Cancer Patients ◽

Long Term Effects ◽

Short Term

283 Background: Hormonal therapy is an important therapeutic modality in both early and metastatic prostate cancer. Whilst the long term effects of androgen deprivation (AD) have been extensively studied, little attention has focussed on assessing short-term vasomotor and psychological effects and the resulting impact of quality of life (QoL) in prostate cancer, relying on data mainly extrapolated from breast cancer patients. This prospective study sought to assess these effects and identify any predictive factors. Methods: Data from 200 consecutive prostate cancer patients were collected from January 2010 to August 2013. A self-reported questionnaire was employed to objectively assess a variety of vasomotor and psychological symptoms, graded from 1 no toxicity, 2 mild, 3 moderate to 4 severe toxicity. Other parameters including height, weight, Body Surface Area (BSA), Body Mass Index (BMI), duration and type of hormonal therapy were also recorded. Results: 181 patients were fully evaluable, with a median age of 75 (IQR 70.5-80). 166 received an LHRH analogue,11 maximum androgen blockade, and 4 received anti-androgens only. 33 (18.2%) of patients reported no toxicity, with 76 (42%), 55 (30%) and 17 (9.4%) experiencing mild, moderate and severe (debilitating) symptoms respectively. The commonest debilitating symptoms were vasomotor: drenching sweats (82%), and hot flashes (82%), which usually coexisted, and less commonly psychological: sleep disturbances (18%) and tiredness (12%). Age (median: 77 vs. 74 yrs), weight (median: 79.8 vs. 84.4), and BMI (median: 26.6 vs. 28.3) significantly predicted between those with grade 1/2 and grade 3/4 symptoms, (p=0.0007, 0.02, 0.02). A non-significant trend was observed with increasing duration of hormonal treatment and toxicity (median: 5, 7, 9.5 and 12 months for Grade 1-4, respectively, p=0.07). Conclusions: The short term side-effect profile of hormonal therapy for prostate cancer is generally favourable, though debilitating predominantly vasomotor symptoms can occur in a significant minority of cases. Increasing age, weight, and BMI may be predictive of toxicity.

Download Full-text

Exercise, sleep quality, and mediators of sleep in breast and prostate cancer patients receiving radiation therapy

Community Oncology ◽

10.1016/s1548-5315(11)70427-2 ◽

2010 ◽

Vol 7 (10) ◽

pp. 463-471 ◽

Cited By ~ 51

Author(s):

Lisa K. Sprod ◽

Oxana G. Palesh ◽

Michelle C. Janelsins ◽

Luke J. Peppone ◽

Charles E. Heckler ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Sleep Quality ◽

Cancer Patients ◽

Breast And Prostate Cancer

Download Full-text

Prevalence of early-stage prostate and estrogen receptor positive (ER+) breast cancer patients receiving primary androgen deprivation therapy (ADT) and aromatase inhibitors (AIs) in the United States (U.S.)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22126 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22126-e22126

Author(s):

A. Barlev ◽

M. Yong ◽

G. Cherkowski ◽

K. Cetin ◽

J. Fryzek

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Clinical Practice ◽

Hormone Therapy ◽

Cancer Patients ◽

Early Stage ◽

Breast Cancer Patients ◽

Claims Database ◽

Breast And Prostate Cancer ◽

The U.S

e22126 Background: AIs and ADT are used to prevent recurrence of breast and prostate cancers but have been shown to accelerate bone loss. We estimated the prevalence of early-stage ER+ breast and prostate cancer patients on hormone therapy in the U.S., as this is not well-described in the literature. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) Program, published literature, clinical practice, and a large claims database were used. We began with the American Cancer Society's estimated number of new breast and prostate cancer cases for the year 2008. We then assessed the number of patients with localized/regional disease and ER+ tumors and those receiving primary ADT (both chemical and surgical) or AI therapy by applying proportions from SEER, published literature, clinical practice, and the claims database. Using these incident case counts, we calculated the 5-year prevalence using appropriate cohort-specific survival rates to sum the number of new and surviving cases over a 5-year period. Results: The estimated 5-year prevalence of early-stage ER+ breast cancer for women aged ≥50 years in the U.S. was 607,411, of which 293,904 (48.4%) were on AI therapy based on the claims database. However, because this data source was limited to women aged <65 years, we also used estimates from clinical practice to capture AI use for women of all ages. Based on clinical practice, 402,637 (66.3%) to 460,156 (75.8%) of early-stage ER+ breast cancer patients were on AI therapy. For early-stage prostate cancer, the estimated 5-year prevalence for all ages was 1,024,238, of which 141,451 (13.8%) were on primary ADT. However, these figures may underestimate current usage of hormone therapies, as our data and the literature show increasing trends in ADT and AI use for early-stage disease. Conclusions: Based on a combination of population-based data and the published literature, approximately half of all early-stage ER+ breast cancer patients and a modest proportion of early-stage prostate cancer patients are on hormone therapy in the U.S. [Table: see text]

Download Full-text

Hubungan Stres Dengan Kualitas Tidur Pada Pasien Kanker Yang Menjalani Kemoterapi Pada Saat Pandemi Covid-19 Di RSUP Dr. M.Djamil Padang

Jurnal Keperawatan Muhammadiyah ◽

10.30651/jkm.v6i2.8234 ◽

2021 ◽

Vol 6 (2) ◽

Author(s):

Weny Amelia ◽

Lola Despitasari ◽

Fitria Alisa

Keyword(s):

Sleep Quality ◽

Cancer Patients ◽

Psychological Health ◽

Sleep Disturbances ◽

Sampling Technique ◽

Cross Sectional Study ◽

P Value ◽

Breast Cancer Patients ◽

Survey Analysis ◽

Cross Sectional

The condition of the COVID-19 pandemic is a threatening condition for cancer sufferers. Management of cancer patients can be done by surgery, chemotherapy, radiotherapy and hormone therapy to treat cancer. For cancer patients infected with COVID-19, adequate protective equipment is needed. Symptoms of COVID-19 that cause people to suffer from cancer or are being treated for cancer that can be more severe, such as high fever, chest pain, bluish lips and nails, shortness of breath, to loss of consciousness or coma. The process during treatment for cancer can affect the psychological health and physical health of patients in the form of illness, stress, illness and sleep disorders. The purpose of this study was to see the relationship between stress and sleep quality in cancer patients undergoing chemotherapy during the Covid-19 pandemic at Dr. M. Djamil Padang. This type of research is the type of research used is a survey analysis, namely to see the events studied using the research design used is a cross sectional study. The sample in this study were breast cancer patients who underwent chemotherapy during the Covid-19 pandemic with accidental sampling technique. The stress instrument uses the DASS (Depressi On Anxiety Stress Scale) 42 which consists of 14 questions about stress, while the sleep quality instrument uses the Pitssburgh Sleep Quality Index (PSQI) questionnaire. The questionnaire consisted of 18 questions including seven components of sleep quality, sleep latency, sleep duration, sleep disturbances, use of sleeping pills, and daytime activity dysfunction. The results of this study were processed using the Chi-Square test. The results showed a relationship between stress and sleep quality in cancer patients undergoing chemotherapy during the Covid-19 pandemic (p value = 0.000; α = 0.05).

Download Full-text

Symposium: Psychosocial and biomarker correlates of sleep quality and quantity in breast and prostate cancer patients and survivors

PsycEXTRA Dataset ◽

10.1037/e548132012-016 ◽

2010 ◽

Author(s):

Wayne Bardwell

Keyword(s):

Prostate Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Breast And Prostate Cancer

Download Full-text

BEHAVIORAL MEDICINE SOLUTIONS FOR OVERWEIGHT AND OBESE BREAST CANCER PATIENTS WITH SLEEP DISTURBANCES

Romanian Medical Journal ◽

10.37897/rmj.2016.3.8 ◽

2016 ◽

Vol 63 (3) ◽

pp. 227-232

Author(s):

Diana V. Artene ◽

◽

Cristian I. Bordea ◽

Alexandru Blidaru ◽

◽

...

Keyword(s):

Breast Cancer ◽

Weight Loss ◽

Body Composition ◽

Sleep Quality ◽

Cancer Patients ◽

Body Fat ◽

Visceral Fat ◽

Sleep Disturbances ◽

Breast Cancer Patients ◽

Depressive Patients

Sleep disturbances overthrow breast cancer patients’ eating behavior, aggravating sarcopenic obesity causes like insulin, leptin and dopamine resistance, thus increasing recurrence and mortality risks. Seeking fat loss solutions for sarcopenic obesity in ER+ breast cancer patients with sleep disturbances, we randomized 50 – of which 16 were depressive – to follow a high protein diet (D) or the diet and sleep journal interventions (D+SJ). Patients ate only when hungry foods naturally high in protein, calcium, omega-3, pre- and probiotics, and were asked to write a daily food journal. Half of the patients were asked to write a 7-day Kalionka Institute type sleep journal – containing questions about the time it took them to fall asleep, number of awakenings during the night, how much they slept, how much they stayed in bed, and self-perceived sleep quality. After writing the sleep journal, we asked patients to follow set sleeping and wake up hours calculated based on their SJ answers, and to not sleep during the day. After 8 weeks we remeasured body composition with a multi-frequency bioelectrical impedance scale. 8 patients from the D+SJ group asked to leave the study, 5 being depressive. D group lost 2.31±2.86% body fat (p=0.001), and 0.76±1.16% visceral fat (p=0.001); with no fat loss difference between patients with or without depression. Depressive patients did not obtain statistically significance for weight loss. D+SJ group improved sleep quality and lost 2.16±2.35% body fat (p=0.002), and 0.86±1.24% visceral fat (p=0.005). Depressive patients didn’t obtain statistically significant results neither for fat, nor for weight loss – maybe because of the overtiring effect of the SJ intervention. So, both D and D+SJ interventions improve breast cancer patients’ body composition despite sleep disturbances, but only non-depressive patients also lose weight. And SJ intervention improves sleep quality in patients without depression, decreasing weight regain risk.

Download Full-text

Evaluating the prevalence and nature of sleep disturbances in prostate cancer patients receiving androgen deprivation therapy using a combination of actigraphy and sleep questionnaires.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e17046 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e17046-e17046

Author(s):

Stephen Mangar ◽

Shalini Mondal ◽

Steve Edwards ◽

Hashim Uddin Ahmed ◽

Richard J Wassersug ◽

...

Keyword(s):

Prostate Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Sleep Disturbances ◽

Androgen Deprivation ◽

Poor Sleep ◽

Poor Sleep Quality ◽

Treatment Naïve ◽

Sleep Questionnaires

e17046 Background: Sleep disturbances and cancer related fatigue are commonly associated. Prostate cancer patients may suffer from disturbed sleep as a result of their diagnosis and following treatment, especially with androgen deprivation therapy (ADT). Wrist actigraphy is a non-invasive objective method of sleep data collection. This feasibility study compares sleep data obtained by actigraphy with subjective data from sleep questionnaires in order to determine the nature and severity of sleep disturbances in patients with and without ADT use. Methods: A prospective cross-sectional pilot study was conducted on 74 patients with prostate cancer attending a regional oncology clinic. Two validated subjective sleep questionnaires namely the Pittsburgh Sleep Quality Index [PSQI] and the Epworth Sleepiness Scale [ESS] were used. Patients wore actigraphy watches for a minimum of five consecutive days. The parameters of interest included: actual sleep time, sleep efficiency, fragmentation index, daytime napping frequency and duration. The questionnaire and actigraphy data were compared between 20 patients receiving ADT and 41 who were treatment-naive. Results: The compliance rate for completed actigraphy was 85%. Complete data sets with actigraphy and questionnaires were available from 61 patients. Those already receiving ADT were on LHRH analogues for a median duration of 2.35 years. Poor sleep quality as self-identified by patients from the PSQI (cut-off > 5) was 49% in the treatment-naive group which increased to 70% for those on ADT. For daytime sleepiness as assessed by ESS (cut-off > 10) this was 16% and 20% respectively. Actigraphy showed that patients on ADT reported longer sleep duration (7.4 vs 6.5 hours, p = 0.02), higher levels of nocturnal wakings (51.1% vs 36.7%, p = 0.002), with greater daytime napping duration (80.7mins vs 53.0mins, p = 0.04), and frequency (8.6 vs 5.6, p = 0.02) compared to treatment-naive patients. Conclusions: Self-reported poor sleep quality is common in prostate cancer patients, which appears worse for those receiving ADT. In patients receiving ADT, data derived from actigraphy suggests that although they were sleeping for longer at night, the quality of sleep was poor which, in turn, may be responsible for an increase in the frequency and duration of daytime napping. Based on the current findings, we recommend the use of actigraphy to characterise patients’ sleep patterns and to assess if sleep treatment is needed. Actigraphic data may allow for direct comparisons of different hormonal agents on sleep whilst identifying those with specific sleep disorders amenable to therapeutic intervention.

Download Full-text